VTGN — Vistagen Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1411685 ·
Last close
$0.27
Market Cap
$11.98M
52W High
$5.14
52W Low
$0.20
ADV30
20,727,817
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,476,000 | — | -13,348,000 | -13,030,000 | 35,736,000 | 16,991,000 | 11,255,000 |
| Mar 2026 | 465,000 | — | -16,717,000 | -16,274,000 | 48,564,000 | 30,789,000 | 13,044,000 |
| Dec 2025 | 303,000 | — | -19,546,000 | -18,899,000 | 65,056,000 | 47,371,000 | 14,136,000 |
| Sep 2025 | 258,000 | — | -20,053,000 | -19,417,000 | 80,929,000 | 62,786,000 | 14,590,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,436,000
Investing CF
$-877,000
Financing CF
$30,971,000
CapEx
$-239,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-477,317,000
Inventory
—
Receivables
—
ST Investments
$14,614,000
EBIT TTM
$-72,120,000
Pretax Income TTM
$-69,678,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,501,000
EBITDA
$-69,459,000
Free Cash Flow
$-36,950,752
Enterprise Value
$-20,429,672
Total Cash
$31,730,000
Total Debt
$783,000
Shares Out
44,376,911
Trailing EPS
$-1.66
Book Value
$0.55
ROE
-166.5%
ROA
-83.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,269,000 | -72,126,000 | -69,685,000 | 48,564,000 | 13,044,000 | 35,520,000 | -66,436,000 |
| Mar 2025 | 486,000 | -55,973,000 | -51,418,000 | 84,341,000 | 13,951,000 | 70,390,000 | -42,097,000 |
| Mar 2024 | 1,064,000 | -33,021,000 | -29,362,000 | 123,653,000 | 9,367,000 | 114,286,000 | -25,813,000 |
| Mar 2023 | -227,000 | -59,268,000 | -59,248,000 | 21,089,000 | 9,009,000 | 12,080,000 | -49,716,000 |
TTM Snapshot
Revenues TTM
$495,000
NetIncome TTM
$-17,083,000
OpCashFlow TTM
$0
Assets (Latest)
$84,341,000
Forward EPS
$-1.54
Max Pain — expiry 2026-11-20
max pain strike: $0.50 · spot: $0.27 · call oi: 4,557 · put oi: 1,107
Expected Move to 2026-11-20:
±$0.23
(85.19%) —
implied range
$0.04 –
$0.50
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CALC | CalciMedica, Inc. | $11.95M | $1.75 | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.73M | $1.01 | — |
| MBRX | Moleculin Biotech, Inc. | $11.73M | $0.60 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $11.67M | $8.32 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.64M | $2.63 | — |
News headlines (Yahoo Finance, 1h cache)
2 Falling Stocks Call Traders Are Targeting Today
2026-09-25 14:50 · Yahoo
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
2026-09-24 13:58 · Yahoo
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
2026-09-24 11:00 · Yahoo
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026-09-22 12:30 · Yahoo
Vistagen to Present at Psych Congress 2026
2026-09-10 12:30 · Yahoo
SRX Global Acquires Stake in Vistagen Therapeutics
2026-08-04 15:35 · Yahoo
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
2026-08-04 09:00 · Yahoo
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
2026-09-24 16:30 · Yahoo
Vistagen Appoints Douglas J. Williamson to its Board of Directors
2026-07-31 12:30 · Yahoo
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026-06-09 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.